125 related articles for article (PubMed ID: 8717113)
1. The impact of osteonectin for differential diagnosis of osteogenic bone tumors: an immunohistochemical and in situ hybridization approach.
Park YK; Yang MH; Park HR
Skeletal Radiol; 1996 Jan; 25(1):13-7. PubMed ID: 8717113
[TBL] [Abstract][Full Text] [Related]
2. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
3. The impact of osteonectin for differential diagnosis of bone tumors. An immunohistochemical approach.
Bosse A; Vollmer E; Böcker W; Roessner A; Wuisman P; Jones D; Fisher LW
Pathol Res Pract; 1990 Oct; 186(5):651-7. PubMed ID: 2287591
[TBL] [Abstract][Full Text] [Related]
4. Osteocalcin and Osteonectin Expression in Canine Osteosarcoma.
Wehrle-Martinez AS; Dittmer KE; Aberdein D; Thompson KG
Vet Pathol; 2016 Jul; 53(4):781-7. PubMed ID: 26926085
[TBL] [Abstract][Full Text] [Related]
5. Histogenesis of clear cell chondrosarcoma. An immunohistochemical study with osteonectin, a non-collagenous structure protein.
Bosse A; Ueda Y; Wuisman P; Jones DB; Vollmer E; Roessner A
J Cancer Res Clin Oncol; 1991; 117(1):43-9. PubMed ID: 1997469
[TBL] [Abstract][Full Text] [Related]
6. Vimentin, osteocalcin and osteonectin expression in canine primary bone tumors: diagnostic and prognostic implications.
Amaral CB; Leite JDS; Fonseca ABM; Ferreira AMR
Mol Biol Rep; 2018 Oct; 45(5):1289-1296. PubMed ID: 30066297
[TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemical localization of bone Gla protein and osteonectin in normal human bone and cartilage tissues, and in osteosarcomas and chondrosarcomas].
Chiba H; Matsuyama T
Nihon Seikeigeka Gakkai Zasshi; 1993 May; 67(5):463-72. PubMed ID: 8336066
[TBL] [Abstract][Full Text] [Related]
8. Osteonectin in osteosarcomas: a marker for differential diagnosis and/or prognosis?
Wuisman P; Roessner A; Bosse A; Ueda Y; Winkelmann W; Enneking WF
Ann Oncol; 1992 Apr; 3 Suppl 2():S33-5. PubMed ID: 1622861
[TBL] [Abstract][Full Text] [Related]
9. KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics.
Jiang L; Liu J; Wei Q; Wang Y
Diagn Pathol; 2020 Nov; 15(1):135. PubMed ID: 33176814
[TBL] [Abstract][Full Text] [Related]
10. Osteocalcin expression in primary bone tumors--in situ hybridization and immunohistochemical study.
Park YK; Yang MH; Kim YW; Park HR
J Korean Med Sci; 1995 Aug; 10(4):263-8. PubMed ID: 8593206
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors.
Serra M; Morini MC; Scotlandi K; Fisher LW; Zini N; Colombo MP; Campanacci M; Maraldi NM; Olivari S; Baldini N
Hum Pathol; 1992 Dec; 23(12):1326-31. PubMed ID: 1468768
[TBL] [Abstract][Full Text] [Related]
12. Small cell osteosarcoma of bone: an immunohistochemical study with differential diagnostic considerations.
Devaney K; Vinh TN; Sweet DE
Hum Pathol; 1993 Nov; 24(11):1211-25. PubMed ID: 7503935
[TBL] [Abstract][Full Text] [Related]
13. Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma.
Gomez-Brouchet A; Mourcin F; Gourraud PA; Bouvier C; De Pinieux G; Le Guelec S; Brousset P; Delisle MB; Schiff C
Hum Pathol; 2010 Sep; 41(9):1220-30. PubMed ID: 20399482
[TBL] [Abstract][Full Text] [Related]
14. Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.
Machado I; López Guerrero JA; Navarro S; Mayordomo E; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2013 Jun; 462(6):665-71. PubMed ID: 23681112
[TBL] [Abstract][Full Text] [Related]
15. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.
Daugaard S; Christensen LH; Høgdall E
APMIS; 2009 Jul; 117(7):518-25. PubMed ID: 19594492
[TBL] [Abstract][Full Text] [Related]
16. Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.
Salas S; de Pinieux G; Gomez-Brouchet A; Larrousserie F; Leroy X; Aubert S; Decouvelaere AV; Giorgi R; Fernandez C; Bouvier C
Virchows Arch; 2009 Jan; 454(1):81-7. PubMed ID: 19050913
[TBL] [Abstract][Full Text] [Related]
17. Histological and immunohistochemical diversities, and proliferative activity and grading in osteosarcomas.
Hasegawa T; Hirose T; Seki K; Hizawa K; Ishii S; Wakabayashi J
Cancer Detect Prev; 1997; 21(3):280-7. PubMed ID: 9167046
[TBL] [Abstract][Full Text] [Related]
18. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting.
Hameetman L; Kok P; Eilers PH; Cleton-Jansen AM; Hogendoorn PC; Bovée JV
Virchows Arch; 2005 Apr; 446(4):430-7. PubMed ID: 15744499
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of osteonectin in various types of osteosarcoma.
Schulz A; Jundt G; Berghäuser KH; Gehron-Robey P; Termine JD
Am J Pathol; 1988 Aug; 132(2):233-8. PubMed ID: 3165250
[TBL] [Abstract][Full Text] [Related]
20. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
